ArticleFuture oncology (London, England)2025
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China.
Andong Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.